Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer

Human Pathology

Volumn 44, Issue 5, 2013, Pages 697-705

  Horcic, Milo ^a   Koelzer, Viktor H ^b   Karamitopoulou, Eva ^b   Terracciano, Luigi ^c   Puppa, Giacomo ^d   Zlobec, Inti ^b   Lugli, Alessandro ^b  

^a Institute of Diagnostic Histology and Cytology Aarau   (Czech Republic)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d Division of Pathology   (Italy)

Author keywords

Colorectal cancer; Prognostic factor; Scoring system; Tumor budding

Indexed keywords

CYTOKERATIN; PANCYTOKERATIN; UNCLASSIFIED DRUG;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; ONCOLOGICAL PARAMETERS; PREDICTIVE VALUE; QUANTITATIVE ANALYSIS; SCORING SYSTEM; TUMOR BUDDING; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OBSERVER VARIATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84876492781     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.07.026     Document Type: Article

References (32)

1. R. Labianca, B. Nordlinger, G.D. Beretta ESMO Guidelines Working Group Primary colon cancer: ESMO clinical practice guidelines for diagnosis, adjuvant treatment and follow-up Ann Oncol 21(Suppl 5) 2010 v70 v77
2. A. Sobrero Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal Lancet Oncol 7 2006 515 516
3. A. Figueredo, M.E. Coombes, and S. Mukherjee Adjuvant therapy for completely resected stage II colon cancer The Cochrane Library, Issue 3 2008 John Wiley & Sons, Ltd Chichester, UK
4. H.M. Quah, J.F. Chou, and M. Gonen Identification of patients with high-risk stage II colon cancer for adjuvant therapy Dis Colon Rectum 51 2008 503 507
5. S.R. Hamilton, F.T. Bosman, and P. Boffetta Adjuvant therapy for completely resected stage II colon cancer F.T. Bosman, WHO classification of tumors of the digestive system 2010 International Agency for Research on Cancer (IARC) Lyon, France 144 146
6. Compton CC. Pathology and prognostic determinants of colorectal cancer. UpToDate 2012; Topic 2484, Version 32.0. http//www.uptodate.com/contents/ pathology-and-prognostic-determinants-of-colorectal-cancer.
7. F. Prall Tumour budding in colorectal carcinoma Histopathology 50 2007 151 162 (Pubitemid 44953405)
8. M. Iwatsuki, K. Mimori, and T. Yokobori Epithelial-mesenchymal transition in cancer development and its clinical significance Cancer Sci 101 2010 293 299
9. T. Kaihara, T. Kusaka, and M. Nishi Dedifferentiation and decreased expression of adhesion molecules, E-cadherin and ZO-1, in colorectal cancer are closely related to liver metastasis J Exp Clin Cancer Res 22 2003 117 123 (Pubitemid 36396666)
10. T. Masaki, H. Matsuoka, and M. Sugiyama Laminin-5 gamma 2 chain and matrix metalloproteinase-2 may trigger colorectal carcinoma invasiveness through formation of budding tumor cells Anticancer Res 23 2003 4113 4119 (Pubitemid 37474907)
11. D.K. Sohn, H.J. Chang, and J.W. Park Histopathological risk factors for lymph node metastasis in submucosal invasive colorectal carcinoma of pedunculated or semipedunculated type J ClinPathol 60 2007 912 915 (Pubitemid 47234439)
12. F. Prall, H. Nizze, and M. Barten Tumour budding as prognostic factor in stage I/II colorectal carcinoma Histopathology 47 2005 17 24 (Pubitemid 40978809)
13. L.M. Wang, D. Kevans, and H. Mulcahy Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer Am J Surg Pathol 33 2009 134 141
14. K. Hase, C. Shatney, and D. Johnson Prognostic value of tumor "budding" in patients with colorectal cancer Dis Colon Rectum 36 1993 627 635 (Pubitemid 23206317)
15. H. Kanazawa, H. Mitomi, and Y. Nishiyama Tumour budding at invasive margins and outcome in colorectal cancer Colorectal Dis 10 2008 41 47 (Pubitemid 350238562)
16. T. Nakamura, H. Mitomi, and S. Kikuchi Evaluation of the usefulness of tumor budding on the prediction of metastasis to the lung and liver after curative excision of colorectal cancer Hepatogastroenterology 52 2005 1432 1435 (Pubitemid 41391008)
17. T. Nakamura, H. Mitomi, and H. Kanazawa Tumor budding as an index to identify high-risk patients with stage II colon cancer Dis Colon Rectum 51 2008 568 572
18. H. Ueno, H. Mochizuki, and E. Shinto Histologic indices in biopsy specimens for estimating the probability of extended local spread in patients with rectal carcinoma Cancer 94 2002 2882 2891 (Pubitemid 34547687)
19. H. Ueno, H. Mochizuki, and Y. Hashiguchi Risk factors for an adverse outcome in early invasive colorectal carcinoma Gastroenterology 127 2004 385 394 (Pubitemid 39091886)
20. A. Lugli, E. Karamitopoulou, and I. Panayiotides CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a "pro-/anti-tumour" approach to tumour host interaction in colorectal cancer Br J Cancer 101 2009 1382 1392
21. P.J. Heagerty, T. Lumley, and M.S. Pepe Time-dependent ROC curves for censored survival data and a diagnostic marker Biometrics 56 2000 337 344 (Pubitemid 30422619)
22. T.V. Perneger What's wrong with Bonferroni adjustments Br Med J 316 1998 1236 1238 (Pubitemid 28171344)
23. K. Ohtsuki, F. Koyama, and T. Tamura Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma Anticancer Res 28 2008 1831 1836 (Pubitemid 351892892)
24. I. Zlobec, L.M. Terracciano, and A. Lugli Local recurrence in mismatch repair-proficient colon cancer predicted by an infiltrative tumor border and lack of CD8+ tumor-infiltrating lymphocytes Clin Cancer Res 14 2008 3792 3797
25. I. Zlobec, K. Baker, and P. Minoo Tumor border configuration added to TNM staging better stratifies stage II colorectal cancer patients into prognostic subgroups Cancer 115 2009 4021 4029
26. M. Tanaka, Y. Hashiguchi, and H. Ueno Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer Dis Colon Rectum 46 2003 1054 1059 (Pubitemid 36992987)
27. L. Losi, B. Baisse, and H. Bouzourene Evolution of intratumoral genetic heterogeneity during colorectal cancer progression Carcinogenesis 26 2005 916 922 (Pubitemid 41214320)
28. M.J. Gardner, and D.G. Altman Confidence intervals rather than P values: estimation rather than hypothesis testing Br Med J 292 1986 746 750 (Pubitemid 16167414)
29. A.L. Canney, D. Kevans, and L.M. Wang Stage II colonic adenocarcinoma: a detailed study of pT4N0 with emphasis on peritoneal involvement and the role of tumour budding Histopathology 61 2012 488 496
30. B.D. Hayes, A. Maguire, and N. Conlon Reproducibility of the rapid bud count method for assessment of tumor budding in stage II colorectal cancer Am J Surg Pathol 34 2010 746 748
31. C.H. Köhne Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? Against the proposal Lancet Oncol 7 2006 516 517
32. D.J. Jonker, K. Spithoff, and J. Maroun Adjuvant systemic chemotherapy for stage II and III colon cancer after complete resection: an updated practice guideline Clin Oncol 23 2011 314 322